Document Detail


Differences among low-molecular-weight heparins: evidence in patients with acute coronary syndromes.
MedLine Citation:
PMID:  19365279     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Low-molecular-weight heparins (LMWHs) have shown equivalent or superior efficacy and safety to unfractionated heparin as antithrombotic agents for the treatment of patients with acute coronary syndromes (ACS). In patients with unstable angina and non-ST segment elevation myocardial infarction (MI), many data support the use of the LMWH enoxaparin to reduce cardiovascular events and death. LMWHs also appear more effective than unfractionated heparin in reducing the composite end point of acute MI, recurrent ischemia, or death in patients with ST segment elevation MI, and can also be used effectively in patients undergoing thrombolysis reperfusion and percutaneous coronary intervention. However, the various LMWH preparations should not be used interchangeably. Each LMWH is a pleiotropic biological agent with a unique chemical, biochemical, biophysical, and biological profile, and it displays a unique pharmacodynamic and pharmacokinetic profile. As a result, LMWHs are not equipotent in preclinical assays or equivalent in terms of their clinical efficacy and safety. Therefore, it is essential that new, emerging, generic versions of LMWHs demonstrate clinical equivalence, in specific indications, with the existing approved LMWHs. This article highlights the chemical, biological, and pharmacological differences between the LMWH preparations that may result in different clinical outcomes during the treatment of patients with acute coronary syndromes.
Authors:
Jose C Nicolau; Marc Cohen; Gilles Montalescot
Related Documents :
18243369 - Intermittent heparin infusion in children with ischemic heart disease caused by kawasak...
18035079 - Adjunctive benefits from low-molecular-weight heparins as compared to unfractionated he...
12052269 - Glycoprotein receptor inhibitors in the management of acute coronary syndromes.
10639269 - The essence trial: efficacy and safety of subcutaneous enoxaparin in unstable angina an...
12082199 - Bleeding complications of platelet glycoprotein iib/iiia inhibitor abciximab (reopro ).
18987409 - 'bail-out' bivalirudin use in patients with thrombotic complications unresponsive to co...
11354569 - Intra- and interhospital repeatability of radionuclide left ventricular ejection fracti...
10963199 - Visualisation of cell death in vivo in patients with acute myocardial infarction.
1733309 - Favorable effects of hyperosmotic reperfusion on myocardial edema and infarct size.
Publication Detail:
Type:  Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  53     ISSN:  1533-4023     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  2009 Jun 
Date Detail:
Created Date:  2009-06-22     Completed Date:  2009-10-08     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  440-5     Citation Subset:  IM    
Affiliation:
Heart Institute (InCor), Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. corjnicolau@incor.usp.br
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Coronary Syndrome / drug therapy*
Angina, Unstable / drug therapy
Anticoagulants* / pharmacokinetics,  therapeutic use
Heparin, Low-Molecular-Weight* / pharmacokinetics,  therapeutic use
Humans
Myocardial Infarction / drug therapy
Therapeutic Equivalency
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Heparin, Low-Molecular-Weight

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effects of novel semiselective matrix metalloproteinase inhibitors on ex vivo cardiac structure-func...
Next Document:  Ion channels, transporters, and pumps as targets for heart failure therapy.